Deepank Utkhede

Deepank is currently the Chief Scientific Officer of Mati Therapeutics. Mr. Utkhede is the former Senior Director of Pharmaceutical Development at QLT Inc. Mr. Utkhede has over 15 years of experience in formulation and process development with a proven track record for solving difficult to manufacture products within aggressive timelines, and for developing robust and commercially scalable manufacturing processes. Mr. Utkhede has worked with various dosage forms -- topicals (dermal and ocular), orals (capsules and liquid), parenterals (aseptic and terminally sterilized) – and drug/device combination products with extensive experience in the area of lyophilization, liposome and emulsion technology. Mr. Utkhede has also been involved in the critical review of CMC section for potential business development in-licensing opportunities. Mr Utkhede will lead efforts for new formulations work on the punctal plug drug delivery platform and will be responsible for commercial scale- up and manufacturing of Phase III and commercial supplies of the first product, latanoprost. Mr. Utkhede has a Master of Science in Biochemistry from the University of British Columbia.